about
Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of ActionResistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitorsContribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapyA picomolar inhibitor of resistant strains of human immunodeficiency virus protease identified by a combinatorial approach.Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individualsInsertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.Protective hybrid coating containing silver, copper and zinc cations effective against human immunodeficiency virus and other enveloped viruses.Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic CellsDevelopment of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individualsSensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.Viral drug resistance and fitness.Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations.Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.Synthesis and biological profiling of 6- or 7-(het)aryl-7-deazapurine 4'-C-methylribonucleosides.Synthesis and biological activity of benzo-fused 7-deazaadenosine analogues. 5- and 6-substituted 4-amino- or 4-alkylpyrimido[4,5-b]indole ribonucleosides.Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity.Highly functionalized and potent antiviral cyclopentane derivatives formed by a tandem process consisting of organometallic, transition-metal-catalyzed, and radical reaction steps.Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness.Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIβ (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology.Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly.Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors.Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor.Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antConfigurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase.PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.Role of Baseline pol Genotype in HIV-1 Fitness Evolution.A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART.The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells.Does BCA3 Play a Role in the HIV-1 Replication Cycle?Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5
P50
Q27700228-4BDE16B3-0778-41AB-91F4-33795905249FQ28533830-5EC3CDB8-846E-4EEF-828C-B61D1441C71CQ28541754-28AFC401-63A4-4E5E-BD6E-434127311D63Q30951274-49554A2C-5461-4CEE-8A5A-3CA556CD21FBQ33907525-80DE3954-34C0-4E6C-92AB-F00CA46DC539Q34020111-07BCA182-CA19-4E62-BC02-1904986CE748Q34348774-C0DEF706-D88B-4228-A822-CC640FDF48FDQ34482589-64BDA402-76DC-49BB-9AA9-EEA15EF3A18DQ35182388-18BA8138-7137-43C2-929C-5F16CB3A72ACQ35977073-3D87AFB0-D5F4-42EA-AAD6-D5811A2C61B7Q36039695-1EC4AB0A-9433-4C9D-9610-2F56165B014EQ36596027-BD723233-C8E8-4A5D-BB51-1D26F37D8320Q36826759-DC7A4C0A-C889-48B2-A15C-446E042BF26CQ37034618-4703D9B5-2E97-46FC-8B6C-DE5710FE52B8Q37256312-F55BF928-B136-4C9B-9C06-6EC59FE5DA65Q37447167-5418A7CD-9769-4564-A5E3-BC2810F81410Q37713470-169871CC-77D5-4720-A634-59C9868CA6BFQ38820222-15B09C8A-D636-4F0F-9AE4-94A4429FCD5FQ39130394-5A698B91-D1AD-4DE5-868E-CCE84205F99FQ40164131-61908FB6-2587-47B6-BFCA-3213AB759E07Q40199626-A6A853BB-E638-4DB0-9B40-D938FE51C323Q40281163-1705578E-E141-4DFF-94E3-ADAEBF4DD133Q40399208-F8DA6997-5842-40F7-BBBB-711C8FC22E60Q40633207-94B160F9-FBC5-49E2-AD37-3476C34D46B8Q40793735-8D1467C0-E88B-4A5B-886E-D7F990E753C4Q41442854-FDB759DB-6944-4A79-911F-C0EF3BE8B047Q41766427-59319BAE-B847-4DFD-9502-3D7F6FC99F5AQ42148219-6F1E9A16-8153-48D9-B666-BAA2350E1E29Q42545682-C33AFD8A-5C4C-4B33-8093-843745618431Q43010726-5D568C93-EF48-49C6-BDC7-F1F67FE6C69FQ43588602-20D39CAB-DE5E-413B-9709-190084A3D895Q44335911-6AAA5341-2953-4500-A5DB-983091B99E18Q45722555-84EC3F0D-04B8-48A2-9E76-3619535A571FQ46546965-F22F8411-981E-490C-B6C3-C271CA5A4801Q47564328-24FF7A21-CB5F-4E5C-B122-E5BF8621649FQ52621429-C2671949-A7F5-400C-9521-B38728B2CDAFQ54121472-42FFAC24-DEA4-4F4C-B1B3-90D8E9A59023Q54231564-8496388D-5D5A-4706-BD1C-D912B0E38332Q55689861-7EE9D94E-CC3E-4A7A-B4B8-AFF7B5BF6E4BQ91455016-E0E1B4FC-05EF-4A26-91A2-76265F273D7B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jan Weber
@ast
Jan Weber
@en
Jan Weber
@es
Jan Weber
@nl
Jan Weber
@sl
type
label
Jan Weber
@ast
Jan Weber
@en
Jan Weber
@es
Jan Weber
@nl
Jan Weber
@sl
prefLabel
Jan Weber
@ast
Jan Weber
@en
Jan Weber
@es
Jan Weber
@nl
Jan Weber
@sl
P214
P1053
B-5405-2013
P106
P21
P214
P31
P3829
P496
0000-0002-2799-7352
P734
P7859
viaf-317087122